NCT07014007RecruitingNot Applicable
Open-label Study to Assess the Tolerance and Efficacy of the Product RV4421B-EV0407, Applied in Paediatric and Adult Populations With Mild to Moderate Atopic Dermatitis for 12 Weeks
Pierre Fabre Dermo Cosmetique1 site in 1 country105 target enrollmentStarted: September 30, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 105
- Locations
- 1
- Primary Endpoint
- Local tolerance of the product RV4421B-EV0407 on studied areas
Study Overview
Brief Summary
Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.
This product is already marketed in several countries. The objective of this clinical study is to evaluate the safety and efficacy of the study product when used alone or in association with topical corticosteroid therapy, in an ethnically diverse adult and pediatric population (including dark skin) and over a long period of time with a 12-week follow-up.
5 visits are planned:
- Visit 1: Inclusion visit (Day 1)
- Visit 2: Intermediate visit (Phone visit - Between Day 8 and Day 15)
- Visit 3: Intermediate visit (Day 29 ± 3 days)
- Visit 4: Intermediate visit (Day 57 ± 3 days)
- Visit 5: End of study visit (Day 85 ± 3 days)
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 3 Months to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, with any phototype according to Fitzpatrick classification aged:
- •Group 1 (infants group): from 3 months to 23 months old included
- •Group 2 (children group): from 24 months to 12 years old included
- •Group 3 (teenagers & adults group): from 13 years old
- •Subject with a diagnosis of atopic dermatitis according to the U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis (Williams HC, Burney PG, et al.).
- •Subject with studied areas (lesions and prevailing xerotic areas) limited up to 30% of the body surface area
- •Subject with mild to moderate Atopic Dermatitis
- •Criteria related to treatments and/or products:
- •Topical corticosteroids treatments (following international treatment guidelines for each age sub-group and including investigator agreement) applied on AD lesions areas since 1 to 5 days before the inclusion and ongoing at the time of inclusion. *
- •*The investigator will be authorized to adjust the treatment during the study.
Exclusion Criteria
- •Criteria related to the skin condition or the disease:
- •Infant with Atopic Dermatitis lesions or prevailing xerotic areas located on the diaper (groups 1 & 2)
- •Subject with history of allergy or intolerance to any of the study product(s) ingredients or material used for the research
- •Subject having any other dermatologic condition than Atopic Dermatitis, or characteristics (like tattoo…) on the studied areas liable to interfere with the study assessments
- •Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- •Knowledge of Acquired Immunodeficiency Syndrome or Infectious (acute or chronic)
- •Criteria related to treatments and/or products:
- •Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study
- •Phototherapy performed within 4 weeks before the inclusion visit or planned to be started during the study
- •Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study
- •Systemic corticosteroids treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study
- •Systemic antibiotics for dermatological purposes treatment established or modified within 2 weeks before the inclusion or ongoing or planned to be started during the study
- •Systemic antihistaminic treatment established or modified within 2 weeks before the inclusion
- •Topical treatments (immunomodulators (TIMs), non-steroidal anti-inflammatory, antihistaminic, antibiotics for dermatological purposes or antiseptics) applied on studied areas within 1 week before the inclusion or ongoing or planned to be started during the study
- •Any other topical treatment or product applied on studied areas incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study
- •Skin care product (including moisturizer) applied on the whole body between the evening before the visit and the inclusion.
- •Water and/or any cleansing product, applied on the whole body within 4 hours before the inclusion visit. If there is no studied area on the face, the subject is allowed to do a light face wash without time restriction (especially in the morning of the visit).
- •Subject who plans to modify his/her usual moisturizer (allowed outside studied areas) and/or care habits during the study
- •Treatment of the mother if the subject of group 1 and 2 is breastfed:
- •Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study
- •Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or planned to be started during the study
- •Systemic corticosteroids established or modified within 2 weeks before the inclusion or planned to be started during the study
- •Systemic antihistaminic established or modified within 2 weeks before the inclusion
- •Systemic antibiotics for dermatological purposes established or modified within 1 week before the inclusion or planned to be started during the study
Arms & Interventions
Infant group
Experimental
Subjects aged from 3 months to 23 months old included
Medical device: RV4421B- EV0407 the test product will be applied twice daily alone or in association with topical corticosteroids.
Intervention: RV4421B- EV0407 (Device)
Children group
Experimental
Subjects aged from 24 months to 12 years old included
Medical device: RV4421B- EV0407 the test product will be applied twice daily alone or in association with topical corticosteroids.
Intervention: RV4421B- EV0407 (Device)
Teenagers & adults group
Experimental
Subjects aged from 13 years old
Medical device: RV4421B- EV0407 the test product will be applied twice daily alone or in association with topical corticosteroids.
Intervention: RV4421B- EV0407 (Device)
Outcomes
Primary Outcomes
Local tolerance of the product RV4421B-EV0407 on studied areas
Time Frame: Day 85
The results of the local tolerance will take into account the clinical signs observed by the investigators and the signs reported by the subject and/or the subjects' parent(s) or guardian(s), based on a 5-point scale (From 1 = Excellent tolerance to 5 = Bad tolerance)
Secondary Outcomes
- IGA (Investigator's Global Assessment)(Day 1, Day 29, Day 57 & Day 85)
- Recording of adverse events(From Day 1 to Day 85)
- Local-SCORAD (SCORing Atopic Dermatitis)(Day 1, Day 29, Day 57 & Day 85)
- Local tolerance of the product RV4421B-EV0407 on studied areas at several timepoints(Day 1, 10 to 30 minutes after the first application, Day 29 & Day 57)
- SCORAD (SCORing Atopic Dermatitis)(Day 1, Day 29, Day 57 & Day 85)
- Subject quality of life IDQOL for subjects from 3 months to 3 years included(Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85)
- PO-SCORAD (Patient Oriented SCORing Atopic Dermatitis)(Every 2 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 1 to Day 85)
- SGA (Subject's Global Assessment)(Every 2 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 15 to Day 85)
- Subject quality of life DLQI for subjects from 16 years(Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85)
- Subject quality of life CDLQI for subjects from 4 years to 15 years included(Every 4 weeks ± 2 days (or during the visit at site for sequences close to visit at site) from Day 29 to Day 85)
- Subject's satisfaction questionnaire(at Day 1 (10 to 30 minutes after the 1st product application), within 2 days before Day 29 or at Day 29 (± 3 days), within 2 days before Day 85 or at Day 85 (± 3 days))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 3
Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19Covid19NCT05014373University of the Philippines144
Terminated
Not Applicable
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With DermatomyositisDermatomyositisNCT01140503Stanford University5
Completed
Phase 2
Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionPostpartum DepressionNCT02285504Supernus Pharmaceuticals, Inc.4
Completed
Phase 1
Validation Study of Multiple Probe Compounds for Drug Interaction EvaluationDrug InteractionsNCT00964106GlaxoSmithKline87
Unknown
Phase 2
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®Cystic FibrosisNCT02722122Protalix15